Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Beigene, a leading biotechnology company headquartered in China (CN), is at the forefront of developing innovative therapies for cancer and other serious diseases. Founded in 2010, Beigene has rapidly expanded its operations across major regions, including North America, Europe, and Asia, establishing a strong global presence in the biopharmaceutical industry.
The company is renowned for its robust pipeline of targeted therapies and immuno-oncology products, with a focus on precision medicine. Notable achievements include the successful development of its flagship drug, Brukinsa, which has gained recognition for its efficacy in treating various forms of blood cancer. Beigene's commitment to research and development, coupled with strategic partnerships, positions it as a key player in the competitive landscape of oncology therapeutics.
+2 vs industry average
Beigene’s score of 42 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2025, BeiGene reported total carbon emissions of approximately 745,000,000 kg CO2e, comprising 11,539,000 kg CO2e from Scope 1, 102,622,000 kg CO2e from Scope 2, and 627,386,000 kg CO2e from Scope 3 emissions. This data reflects a comprehensive approach to emissions reporting, including all relevant scopes.
The company has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions to near zero by 2025. Additionally, BeiGene targets a 30% reduction in both Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. Furthermore, they plan to achieve a 25% reduction in Scope 1 and 2 emissions per unit of internally manufactured commercial products by 2026, with 2021 as the baseline.
These initiatives demonstrate BeiGene's commitment to sustainability and align with industry standards for climate action. The emissions data and reduction targets are sourced directly from BeiGene, Ltd., ensuring accuracy and relevance in their climate strategy.
Access structured emission data, company specific factors and auditable source documents
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more